FDA approves AstraZeneca and BMS' diabetes drug FARXIGA
The US Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squibb's (BMS) FARXIGA (dapagliflozin), a once-daily oral treatment for the improvement of glycaemic control in adults with type 2 diabetes mellitus.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Pharmaceuticals